PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)

A Phase I/II, Randomized Pilot Study of the Comparative Safety and Efficacy of Transendocardial Injection of Autologous Mesenchymal Stem Cells Versus Allogeneic Mesenchymal Stem Cells in Patients With Non-ischemic Dilated Cardiomyopathy.

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01392625

Acronym

PoseidonDCM

Enrollment

Registered

2011-07-12

Start date

2011-05-19

Completion date

2017-08-28

Last updated

2018-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-ischemic Dilated Cardiomyopathy

Keywords

Non ischemic dilated cardiomyopathy, Dilated cardiomyopathy, Heart failure, Cardiac Stem Cell Transplantation, Stem Cells

Brief summary

The technique of transplanting progenitor cells into a region of damaged myocardium, termed cellular cardiomyoplasty1, is a potentially new therapeutic modality designed to replace or repair necrotic, scarred, or dysfunctional myocardium2-4. Ideally, graft cells should be readily available, easy to culture to ensure adequate quantities for transplantation, and able to survive in host myocardium; often a hostile environment of limited blood supply and immunorejection. Whether effective cellular regenerative strategies require that administered cells differentiate into adult cardiomyocytes and couple electromechanically with the surrounding myocardium is increasingly controversial and recent evidence suggests that this may not be required for effective cardiac repair. Most importantly, transplantation of graft cells should improve cardiac function and prevent adverse ventricular remodeling. To date, a number of candidate cells have been transplanted in experimental models, including fetal and neonatal cardiomyocytes5, embryonic stem cell-derived myocytes6, 7, tissue engineered contractile grafts8, skeletal myoblasts9, several cell types derived from adult bone marrow10-15, and cardiac precursors residing within the heart itself16. There has been substantial clinical development in the use of whole bone marrow and skeletal myoblast preparations in studies enrolling both post-infarction patients, and patients with chronic ischemic left ventricular dysfunction and heart failure. The effects of bone-marrow derived mesenchymal stem cells (MSCs) have also been studied clinically. Currently, bone marrow or bone marrow-derived cells represent highly promising modality for cardiac repair. The totality of evidence from trials investigating autologous whole bone marrow infusions into patients following myocardial infarction supports the safety of this approach. In terms of efficacy, increases in ejection fraction are reported in the majority of the trials. Non-ischemic dilated cardiomyopathy is a common and problematic condition; definitive therapy in the form of heart transplantation is available to only a tiny minority of eligible patients. Cellular cardiomyoplasty for chronic heart failure has been studied less than for acute MI, but represents a potentially important alternative for this disease.

Detailed description

This is a Pilot Study, intended as a safety assessment prior to a full comparator study. In this Pilot Study, cells administered via the Biosense Webster MyoStar NOGA injection catheter system will be tested in 36 patients in two groups: Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 X 108 (100 million) Auto-hMSCs. Group 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 X 108 (100 million) Auto-hMSCs. The first three (3) patients in each group (Group 1 and Group 2) will not be treated less than 5 days apart and will each undergo full evaluation for 5 days to demonstrate there is no evidence of a procedure induced myocardial infarction or myocardial perforation prior to proceeding with the treatment of further patients. Patients will be randomized in a 1:1 ratio to one of the two groups. Treatment Strategies: Autologous hMSCs vs. Allogeneic hMSCs. The Study Team will record and maintain a detailed record of injection locations. If a patient is randomized to Groups 1 (Auto-hMSCs) and the Auto-hMSCs do not expand to the required dose of 1 X 108 cells, each injection will contain the maximum number of cells available. The injections will be administered transendocardially during cardiac catheterization using the Biosense Webster MyoStar NOGA Catheter System. For patients randomized to Group 1(Auto-hMSCs); the cells will be derived from a sample of the patient's bone marrow (obtained by iliac crest aspiration) approximately 4-6 weeks prior to cardiac catheterization. For patients randomized to Group 2 (Allo- hMSCs), the cells will be supplied from an allogeneic human mesenchymal stem cell source manufactured by the University of Miami. The Allo-hMSCs for patients in group 2 will be administered after all baseline assessments are completed with an expected range of 2 - 4 weeks post-randomization. Following cardiac catheterization and cell injections, patients will be hospitalized for a minimum of 2 days then followed at 2 weeks post-catheterization, and at month 2, 3, 6, and 12 to complete all safety and efficacy assessments.

Interventions

BIOLOGICALAutologous hMSCs

Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection: Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.

BIOLOGICALAllogeneic hMSCs

Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection: Group 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 95 Years

Healthy volunteers

Inclusion criteria

Major Inclusion Criteria: * Be ≥ 18 and \< 95 years of age. * Provide written informed consent. * Diagnosis of nonischemic dilated cardiomyopathy. * Be a candidate for cardiac catheterization within 5 to 10 weeks of screening. * Been treated with appropriate maximal medical therapy for heart failure. * Ejection fraction below 40% and either a left ventricular end diastolic diameter (LVEDD) \> 5.9cm in male subjects, an LVEDD of \> 5.6cm in female subjects or left ventricular end diastolic volume index \> 125 mL/m2 * Be able to undergo an MRI or CT. Major

Exclusion criteria

* Baseline glomerular filtration rate equal or \< 45 ml/min/1.73m2. * Be eligible for or require standard-of-care surgical or percutaneous intervention for the treatment of nonischemic dilated cardiomyopathy. * Presence of a prosthetic aortic valve or heart constrictive device. * Presence of a prosthetic mitral valve. * Previous myocardial infarction (MI) as documented by a clinical history that will include an elevation of cardiac enzymes and/or ECG changes consistent with MI. * Diagnosis of nonischemic dilated cardiomyopathy due to valvular dysfunction, mitral regurgitation, tachycardia, or myocarditis. * Previous treatment for post-infarction left ventricular dysfunction including PCI and thrombolytic therapy. * Documented presence of a known LV thrombus, aortic dissection, or aortic aneurysm. * Documented presence of epicardial stenosis of 70% or greater in one or more major epicardial coronary arteries. * Documented presence of aortic stenosis (aortic stenosis graded as 1.5cm2 or less). * Documented presence of moderate to severe aortic insufficiency (echocardiographic assessment of aortic insufficiency graded as ≥+2). * Evidence of a life-threatening arrhythmia in the absence of a defibrillator (nonsustained ventricular tachycardia ≥ 20 consecutive beats or complete second or third degree heart block in the absence of a functioning pacemaker) or QTc interval \> 550 ms on screening ECG. * AICD firing in the past 30 days prior to the procedure * Be eligible for or require coronary artery revascularization. * Diabetic with poorly controlled blood glucose levels and/or evidence of proliferative retinopathy. * Have a hematologic abnormality as evidenced by hematocrit \< 25%, white blood cell \< 2,500/ul or platelet values \< 100,000/ul without another explanation. * Have liver dysfunction, as evidenced by enzymes (ALT and AST) greater than three times the ULN. * Have a coagulopathy condition = (INR \> 1.3) not due to a reversible cause. * Known, serious radiographic contrast allergy. * Known allergies to penicillin or streptomycin. * Organ transplant recipient. * Have a history of organ or cell transplant rejection * Clinical history of malignancy within 5 years (i.e., patients with prior malignancy must be disease free for 5 years), except curatively-treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma. * Non-cardiac condition that limits lifespan to \< 1 year. * On chronic therapy with immunosuppressant medication. * Serum positive for HIV, hepatitis BsAg, or viremic hepatitis C. * Female patient who is pregnant, nursing, or of child-bearing potential and not using effective birth control. * Have a history of drug or alcohol abuse within the past 24 months. * Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.

Design outcomes

Primary

Measure	Time frame	Description
Incidence of Any Treatment-emergent Serious Adverse Events (TE-SAEs)	One month post-catheterization	Incidence of TE-SAEs is defined as the composite of: death, non-fatal MI, stroke, hospitalization for worsening heart failure, cardiac perforation, pericardial tamponade, sustained ventricular arrhythmias (characterized by ventricular arrhythmias lasting longer than 15 seconds or with hemodynamic compromise), or any other potential late effects detected and corroborated by clinical presentation, laboratory investigations, image analysis and when necessary with biopsy from suspected target sites in the body.

Secondary

Measure	Time frame	Description
Measurement of Changes in Peak VO2	Baseline, 6 month and 12 month	Measurement of Peak oxygen consumption (Peak VO2) by treadmill determination during the 12 month follow-up period.
Measurement of Changes in 6 Minute Walk	Baseline, 6 month and 12 month	Measurement of Six-minute walk test during the 12 month follow-up period
Measurement of Changes in Global Ejection Fraction	Baseline, 6 month and 12 month	Measurement of regional left ventricular function, end diastolic and end systolic volume, measured by MRI, and or CT, and echocardiogram.
Measurement of Changes in New York Heart Association (NYHA)	Baseline, 6 month and 12 month	Measurement of New York Heart Association (NYHA) functional class during the 12 month follow-up period.
Measurement of Changes in Minnesota Living With Heart Failure (MLHF) Questionnaire	Baseline, 6 month and 12 month	Measurement of Minnesota Living with Heart Failure (MLHF) Questionnaire during the 12 month follow-up period. It measures the effects of symptoms, functional limitations, and psychological distress on an individual's quality of life. The response scale for all 21 items on the MLHF is based on a 6-point. The Maximum possible scores being 126 and the minimum 0. Higher scores indicate a worse or worsening quality of life, while lower scores or decreasing scores indicate a better quality of life.

Countries

United States

Participant flow

Participants by arm

Arm	Count
Autologous hMSCs Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs. Autologous hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection: Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.	18
Allogeneic hMSCs Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs. Allogeneic hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection: Group 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.	19
Total	37

Baseline characteristics

Characteristic	Autologous hMSCs	Allogeneic hMSCs	Total
Age, Continuous	57.4 years STANDARD_DEVIATION 11	54.4 years STANDARD_DEVIATION 11.5	55.8 years STANDARD_DEVIATION 11.2
Enrollment End Diastolic diameter (CM)	7.0 centimeters STANDARD_DEVIATION 1.6	7.2 centimeters STANDARD_DEVIATION 1.2	7.1 centimeters STANDARD_DEVIATION 1.4
Ethnicity (NIH/OMB) Hispanic or Latino	8 Participants	4 Participants	12 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	10 Participants	15 Participants	25 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants
New York Heart Association Class Class III - Marked Limitation of Physical Activity	2 Participants	5 Participants	7 Participants
New York Heart Association Class Class II - Slight Limitation of Physical Activity	8 Participants	9 Participants	17 Participants
New York Heart Association Class Class I - no limitation	6 Participants	4 Participants	10 Participants
New York Heart Association Class Class IV -Inability to carry on physical activity	0 Participants	0 Participants	0 Participants
Participants Ejection Fraction % in the trial	21.7 percentage STANDARD_DEVIATION 6.2	22.5 percentage STANDARD_DEVIATION 6.5	22.1 percentage STANDARD_DEVIATION 6.3
Participants Injection status in the trial No	2 Participants	1 Participants	3 Participants
Participants Injection status in the trial Yes	16 Participants	18 Participants	34 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Asian	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Black or African American	1 Participants	2 Participants	3 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	1 Participants	0 Participants	1 Participants
Race (NIH/OMB) White	16 Participants	17 Participants	33 Participants
Sex: Female, Male Female	7 Participants	5 Participants	12 Participants
Sex: Female, Male Male	11 Participants	14 Participants	25 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	2 / 18	0 / 19
other Total, other adverse events	4 / 18	7 / 19
serious Total, serious adverse events	6 / 18	6 / 19

Outcome results

Primary

Incidence of Any Treatment-emergent Serious Adverse Events (TE-SAEs)

Incidence of TE-SAEs is defined as the composite of: death, non-fatal MI, stroke, hospitalization for worsening heart failure, cardiac perforation, pericardial tamponade, sustained ventricular arrhythmias (characterized by ventricular arrhythmias lasting longer than 15 seconds or with hemodynamic compromise), or any other potential late effects detected and corroborated by clinical presentation, laboratory investigations, image analysis and when necessary with biopsy from suspected target sites in the body.

Time frame: One month post-catheterization

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Autologous hMSCs	Incidence of Any Treatment-emergent Serious Adverse Events (TE-SAEs)	Upper respiratory tract infection	1 Participants
Autologous hMSCs	Incidence of Any Treatment-emergent Serious Adverse Events (TE-SAEs)	Ventricular tachycardia	0 Participants
Autologous hMSCs	Incidence of Any Treatment-emergent Serious Adverse Events (TE-SAEs)	Device Pacing issue	0 Participants
Allogeneic hMSCs	Incidence of Any Treatment-emergent Serious Adverse Events (TE-SAEs)	Upper respiratory tract infection	0 Participants
Allogeneic hMSCs	Incidence of Any Treatment-emergent Serious Adverse Events (TE-SAEs)	Ventricular tachycardia	1 Participants
Allogeneic hMSCs	Incidence of Any Treatment-emergent Serious Adverse Events (TE-SAEs)	Device Pacing issue	1 Participants

Secondary